Sigumir
/ Khavinson-tradition joint cartilage bioregulator (AED variant)ALIAS · Sigumir · AED variant (joint) · Joint peptide bioregulator
Terms in this page you can click for a plain-English popup: , , , , , , , .
Tier 4. Khavinson-tradition short-peptide preparation positioned as a cartilage / joint tissue bioregulator. Vendor materials cite an Ala-Glu-Asp (AED) variant as the active. No PubMed-indexed primary literature on Sigumir as a distinct entity.
Sigumir is described in vendor materials as a short-peptide preparation built around an Ala-Glu-Asp (AED) core, marketed for cartilage and joint tissue regulation. Within the Khavinson-tradition framework the claim is tissue-specific modulation of chondrocyte-related gene expression. The molecular target has not been independently characterised, and the AED motif is asserted as the active without consistent published verification of the vendor preparation content.
Tier 4. No PubMed-indexed primary literature distinct from Khavinson-group class-level reviews of cartilage and joint tissue peptide bioregulators.
No formal human safety database. General Khavinson-tradition short-peptide class concerns apply.
Regulatory status
- FDA status:
- Not FDA-approved
The Khavinson school (Saint-Petersburg Institute of Bioregulation and Gerontology) has published an extensive body of work on short-peptide 'bioregulators' derived from animal-tissue extracts, with a unifying claim that tissue-specific tetrapeptides (and shorter motifs) regulate gene expression and tissue-specific cell function. The corpus is Russian-origin and substantially self-cited; independent Western replication of the foundational findings has not been established.
Sigumir is one of several Khavinson-tradition vendor preparations with overlapping AED / AEDG / KED nomenclature; published primary data on the joint-cartilage application is absent. Subjects comparing vendor offerings for joint use cannot evaluate Sigumir against a published clinical record.